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Introduction
A new commercially available dissociation enhanced
lanthanide fluoroimmunoassay (DELFIA) for the
measurement of amniotic fluid 0t fetoprotein has been
evaluated against a monoclonal antibody-based solid-
phase immunoradiometric assay (IRMA) which has been
the routine assay used by a Regional Amniotic Fluid
Alphafetoprotein (AFP) Screening Laboratory for two
years.
The DELFIA (LKB Wallac) AFP assay is a non-isotopic
technique which utilizes a lanthanide metal (Europium)
chelate label possessing highly fluorescent properties
(Soini and Kojola [1]; Hemmila et al. [2]). The assay
incorporates two monoclonal antibodies directed against
two different immunogenic sites on the AFP molecule one
of which is solid phase immobilized to the well of a
microtitration strip.
The aim of this study was to assess the laboratory and
clinical performance of this DELFIA.
Materials and methods
For t fetoprotein analyses, amniotic fluid fetoprotein
(AFP) was estimated by two techniques.
DELFIA AFP 1244-004 (LKB Wallac, PO Box 10, SF20101,
Turku 10, Finland)
This product is a second-generation DELFIA AFP kit.
AFP standards (range 1-1000 KU/1), QC and unknown
samples (25 1) are added to individual wells of microti-
tration strips (12 wells per strip, eight strips per plate)
containing immobilized monoclonal antibody. The mi-
crotitration wells act as both reaction chambers and as
measurement cuvettes. 200 tl of a europium labelled
second monoclonal antibody is pipetted into the wells.
The strips of microtitration wells are shaken vigorously
on an automatic shaking device (Varishaker, Dynatech)
tbr 2 min then incubatedfor h at room temperature with
continuous gentle shaking. The liquid contents of the
wells are aspirated and the wells washed six times with
wash buffer (plate-washing step is also the separation
step), using an automatic plate-washer (LKB 1296-022).
200 1 ofenhancement solution (forms a new chelate with
the europium ion, thus amplifying the fluorescence) is
added to each well and the strips shaken gently for 5 min.
The microtitration strips are allowed to stand for 15 min
and then the fluorescence measured on an automated
LKB Wallac 1230 Arcus fluorometer with automated
data handling. A microtitration plate of 96 wells can be
fully processed with full print-out of patient results in
10 min. AFP results were calculated in kU/l corrected for
.the sample dilution actor and expressed as MU/1. The
shelf life is reported to be at least five months (manu-
facturer’s information).
IRMA (SUCROSEP*) AFP IRMA, Boots-Celltech Diag-
nostics Ltd, Slough, UK
This immunoradiometric assay (IRMA) was performed
using the protocol detailed by the manufacturer, 0t
fetoprotein standard (range 1"23-712 kU/1) or unknown
sample (50 1) is incubated for 2 h at room temperature
(15-30C) with 125 l-labelled monoclonal antibody to 0t
fetoprotein (100 1) and solid phase anti 0t fetoprotein
immunoglobulin (100 1). During this incubation the
assay tubes are shaken vigorously (300-350 min-1) using
an agitator (Sucroagitator, Boots-Celltech Diagnostics
Ltd).
Following incubation the free and bound fractions are
separated by the SUCROSEP sucrose layering non-
centrifugation technique (Wright and Hunter [3]) using
a semi-automatic instrument (Sucroseparator, Boots-
Celltech Diagnostics Ltd). This allows assay tubes to be
rapidly separated in 20-tube batches with a mean asssay
separation time of approximately 50 min.
The radioactivity in the assay tubes was counted on a
multihead gamma counter (LKB 1260 multigamma 11)
over a 120 s period. 0t fetoprotein values for clinical
specimens were calculated as kU/1 by spline function.
The values were then corrected for the sample dilution
factor and expressed as MU/1 0t fetoprotein.
* SUCROSEP is a trademark ofBoots-Celltech Diagnostics Ltd.
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Specimen analysis
Before analysis each amniotic fluid was diluted with a
serum pool ofzero ot fetoprotein free serum. Normally a
in 200 dilution was used, but occasionally a higher
dilution of the amniotic fluid sample was necessary. The
batches for the two techniques were commenced on the
same day with each amniotic fluid assayed in duplicate.
Amnioticfluid samples: 174 aliquots of amniotic fluid were
investigated. These were collected by transabdominal
amniocentesis during the second trimester of pregnancy
for a variety of clinical indications. These samples were
centrifuged and the supernatant either used immediately
or stored at -20C until analysis.
Normal pregnancies: 115 liquors from normal pregnancies
were investigated. Ultrasound examination of these
pregnancies showed no obvious fetal abnormality. The
amniotic fluid AFP by IRMA was within normal
laboratory .reference limits and there was no evidence of
the acetyl cholinesterase isoenzyme band on poly-
acrylamide gel electrophoresis (Chubb et al. [4]; Smith et . [5]).
Statistical methods
Regression analysis was performed using standard tech-
niques.
Results
Assay reproducibility
The intra- and inter-assay coefficients of variation (CV)
for the DELFIA and IRMA were similar (table 1). The
CV ofthe IRMA appeared to be better than the DELFIA
at the highest AFP control pool concentration (sample 3).
The relationship between amniotic fluid AFP levels measured by
DELFIA and IRMA
Regression analysis of results from 174 amniotic fluid
samples (figure 1) falling in the range ofAFP values from
3"4 to 584"0 MU/1 analysed by both methods gave an
excellent correlation coefficient of 0"997 (IRMA 1" 155
DELFIA + 0"946).
Abnormal pregnancies: 55 samples were classified as ’abnor-
mal’. These pregnancies had been terminated and the
fetuses confirmed to have a severe fetal abnormality (27
open spina bifida, 28 anencephaly).
Equivocal pregnancies: Four samples were also studied from
’equivocal pregnancies’ for which the outcome of the
pregnancy was a normal infant but the amniotic fluid 0t
fetoprotein concentration by IRMA was significantly
elevated.
Table 1. Assay reproducibility ofDELFIA and IRMA (intra-
and inter-assay) based on repeated analyses ofcontrol pools. Prior
to assays samples 1 and2 were diluted 1/200, sample3 was diluted
1/600.
MeanAFP
concentration Intra-assay Inter-assay
Sample MU/1 %CV (N= 10) %CV (N= 10)
DELFIA IRMA DELFIA IRMA DELFIA IRMA
1. 26"1 27"5 1"98 1"84 3"72 3"33%
2. 75"9 86"6 1"70 2"72 6"09 5"69%
3. 163" 183"9 6"04 3"30 7"60 4"92%
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Figure 1. Relationship between otfetoprotein values determined by
DELFIA and IRMA for 174 amnioticfluid samples. Not all of
the data points at the lower end ofthe graph are represented. The
line indicated represents DELFIA IRMA.
Table 2. otfetoprotein concentration of115 amnioticfluidsfrom normal pregnancies as measured by DELFIA.
Recommended
Gestational Number of Range ofAFP MedianAFP cutoff[6] level
age samples values (MU/1) concentration ofAFP (MU/1)
15 16 8"3-20"8 13"0
16 20 7"2-15"6 11 "85
17 18 5"3-21"6 9"9
18 20 5"8-14’4 8"15
19 20 3"6-12"6 6"35
20 21 2"8-12"0 5"
32"5
35"6
29"7
24"5
22"2
17"9
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Figure 2. ot-fetoprotein values for 55 abnormal amniotic fluid
samples measured by DELFIA. Where A spina bifida; A
anencephaly; Q) "equivocal pregnancy’," median;
recommended multiple ofthe median cut-off level [6].
Clinical performance ofDELFIA
Table 2 indicates the median AFP concentration of the
normal population for gestational ages of 15 to 20 weeks
as measured by DELFIA.
The AFP levels of the 55 open neural tube defects and for
comparison the median and multiple ofthe median cut off
limits [6] of the normal pregnancy population are shown
in figure 2.
In 53 ofthe 55 cases ofopen spina bifida and anencephaly
the amniotic fluid AFP results as measured by DELFIA
were greater than the multiple of the median cut-off
limits. In two cases ofopen spina bifida the AFP level fell
below the cut-off line (classified as false negative). The
clinical classification of all 55 cases was exactly similar
using either the DELFIA or the IRMA. In the remaining
four amniotic fluids from the ’equivocal pregnancies’ in
which the outcome ofthe pregnancy was a normal infant,
the AFP result as measured by DELFIA was elevated
again, exactly similar to the results ofthe reference IRMA
technique.
Discussion
Excellent agreement was shown between the amniotic
fluid AFP results (r 0"997) of the DELFIA and IRMA
techniques. Furthermore the clinical performance of the
two assays was exactly similar.
Both the DELFIA and IRMA are relatively quick
techniques allowing a same day assay service if requried.
The DELFIA assay was more rapid, largely due to the
need for a h incubation period compared to a 2 h period
for the IRMA.
The equipment requirements of the two assays were
similar, i.e. orbital shakers and a separating system (a
plate-washer or the Sucroseparator), followed by a
radioactivity counter or a fluorimeter. Both techniques do
not require centrifugation steps.
The DELFIA offers a number ofanalytical advantages, a
longer shelflife ofreagents than conventional radioimmu-
noassays and IRMAs, a greater working range (up to
1000 kU/1), a smaller sample volume and a non isotopic
technique which therefore dispenses with the complica-
tions surrounding the safe handling and disposal of
radioactive material.
In summary, the DELFIA proved to be a sensitive,
convenient, easy to use non isotopic alternative to the
measurement of amniotic fluid 0t fetoprotein in the
routine clinical chemistry laboratory.
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